<?xml version="1.0" encoding="UTF-8"?>
<ref id="B28">
 <label>28.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Mossler</surname>
    <given-names>C</given-names>
   </name>, 
   <name name-style="western">
    <surname>Groiss</surname>
    <given-names>F</given-names>
   </name>, 
   <name name-style="western">
    <surname>Wolzt</surname>
    <given-names>M</given-names>
   </name>, 
   <name name-style="western">
    <surname>Wolschek</surname>
    <given-names>M</given-names>
   </name>, 
   <name name-style="western">
    <surname>Seipelt</surname>
    <given-names>J</given-names>
   </name>, 
   <name name-style="western">
    <surname>Muster</surname>
    <given-names>T</given-names>
   </name>
  </person-group>
  <year>2013</year>
  <article-title>Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1</article-title>. 
  <source>Vaccine</source>
  <volume>31</volume>:
  <fpage>6194</fpage>â€“
  <lpage>6200</lpage>. doi:
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.10.061</pub-id>.
  <pub-id pub-id-type="pmid">24183981</pub-id>
 </mixed-citation>
</ref>
